Literature DB >> 11832515

Discrimination of Mycobacterium tuberculosis complex bacteria using novel VNTR-PCR targets.

Robin A Skuce1, Thomas P McCorry, Julie F McCarroll, Solvig M M Roring, Alistair N Scott, David Brittain, Stephen L Hughes, R Glyn Hewinson, Sydney D Neill.   

Abstract

The lack of a convenient high-resolution strain-typing method has hampered the application of molecular epidemiology to the surveillance of bacteria of the Mycobacterium tuberculosis complex, particularly the monitoring of strains of Mycobacterium bovis. With the recent availability of genome sequences for strains of the M. tuberculosis complex, novel PCR-based M. tuberculosis-typing methods have been developed, which target the variable-number tandem repeats (VNTRs) of minisatellite-like mycobacterial interspersed repetitive units (MIRUs), or exact tandem repeats (ETRs). This paper describes the identification of seven VNTR loci in M. tuberculosis H37Rv, the copy number of which varies in other strains of the M. tuberculosis complex. Six of these VNTRs were applied to a panel of 100 different M. bovis isolates, and their discrimination and correlation with spoligotyping and an established set of ETRs were assessed. The number of alleles varied from three to seven at the novel VNTR loci, which differed markedly in their discrimination index. There was positive correlation between spoligotyping, ETR- and VNTR-typing. VNTR-PCR discriminates well between M. bovis strains. Thirty-three allele profiles were identified by the novel VNTRs, 22 for the ETRs and 29 for spoligotyping. When VNTR- and ETR-typing results were combined, a total of 51 different profiles were identified. Digital nomenclature and databasing were intuitive. VNTRs were located both in intergenic regions and annotated ORFs, including PPE (novel glycine-asparigine-rich) proteins, a proposed source of antigenic variation, where VNTRs potentially code repeating amino acid motifs. VNTR-PCR is a valuable tool for strain typing and for the study of the global molecular epidemiology of the M. tuberculosis complex. The novel VNTR targets identified in this study should additionally increase the power of this approach.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832515     DOI: 10.1099/00221287-148-2-519

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  81 in total

1.  Human Mycobacterium bovis infections in London and Southeast England.

Authors:  M J Stone; T J Brown; F A Drobniewski
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Mycobacterial interspersed repetitive unit typing of Mycobacterium tuberculosis compared to IS6110-based restriction fragment length polymorphism analysis for investigation of apparently clustered cases of tuberculosis.

Authors:  Peter M Hawkey; E Grace Smith; Jason T Evans; Philip Monk; Gerry Bryan; Huda H Mohamed; Madhu Bardhan; R Nicholas Pugh
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

3.  Analysis of the allelic diversity of the mycobacterial interspersed repetitive units in Mycobacterium tuberculosis strains of the Beijing family: practical implications and evolutionary considerations.

Authors:  Igor Mokrousov; Olga Narvskaya; Elena Limeschenko; Anna Vyazovaya; Tatiana Otten; Boris Vyshnevskiy
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

4.  High genetic diversity revealed by variable-number tandem repeat genotyping and analysis of hsp65 gene polymorphism in a large collection of "Mycobacterium canettii" strains indicates that the M. tuberculosis complex is a recently emerged clone of "M. canettii".

Authors:  Michel Fabre; Jean-Louis Koeck; Philippe Le Flèche; Fabrice Simon; Vincent Hervé; Gilles Vergnaud; Christine Pourcel
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

5.  First worldwide proficiency study on variable-number tandem-repeat typing of Mycobacterium tuberculosis complex strains.

Authors:  Jessica L de Beer; Kristin Kremer; Csaba Ködmön; Philip Supply; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

6.  Microevolution of Mycobacterium tuberculosis in a tuberculosis patient.

Authors:  Sahal A M Al-Hajoj; Onno Akkerman; Ida Parwati; Saad al-Gamdi; Zeaur Rahim; Dick van Soolingen; Jakko van Ingen; Philip Supply; Adri G M van der Zanden
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

7.  Evaluation of the epidemiological relevance of variable-number tandem-repeat genotyping of Mycobacterium bovis and comparison of the method with IS6110 restriction fragment length polymorphism analysis and spoligotyping.

Authors:  Caroline Allix; Karl Walravens; Claude Saegerman; Jacques Godfroid; Philip Supply; Maryse Fauville-Dufaux
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

8.  Progression toward an improved DNA amplification-based typing technique in the study of Mycobacterium tuberculosis epidemiology.

Authors:  Krishna K Gopaul; Timothy J Brown; Andrea L Gibson; Malcolm D Yates; Francis A Drobniewski
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

9.  Limitations of spoligotyping and variable-number tandem-repeat typing for molecular tracing of Mycobacterium bovis in a high-diversity setting.

Authors:  Sabrina Rodriguez-Campos; Alicia Aranaz; Lucía de Juan; José Luis Sáez-Llorente; Beatriz Romero; Javier Bezos; Antonio Jiménez; Ana Mateos; Lucas Domínguez
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

10.  Molecular typing of Mycobacterium bovis strains isolated in Italy from 2000 to 2006 and evaluation of variable-number tandem repeats for geographically optimized genotyping.

Authors:  M Beatrice Boniotti; Maria Goria; Daniela Loda; Annalisa Garrone; Alessandro Benedetto; Alessandra Mondo; Ernesto Tisato; Mariagrazia Zanoni; Simona Zoppi; Alessandro Dondo; Silvia Tagliabue; Stefano Bonora; Giorgio Zanardi; M Lodovica Pacciarini
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.